NCT06407232View on ClinicalTrials.gov

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant
Interventions
DRUG

Letermovir

480 mg taken orally once daily, for 84 days

Trial Locations (1)

53792

RECRUITING

UW Hospital and Clinics, Madison

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Wisconsin, Madison

OTHER